Aptinyx Inc.
| NASDAQ: APTX |
| Healthcare / Biotechnology / USA |
| 2.66 | -0.0300 | -1.12% | Vol 144.32K | 1Y Perf -38.03% |
| Jul 23rd, 2021 16:00 DELAYED |
| BID | 2.65 | ASK | 2.66 | ||
| Open | 2.69 | Previous Close | 2.69 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 9.71 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 265.04 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 181.34M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 8.63 | Earnings Date | 12th Aug 2021 |
Today's Price Range 2.612.70 | 52W Range 2.306.47 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.14% | ||
| 1 Month | -9.22% | ||
| 3 Months | -2.21% | ||
| 6 Months | -33.50% | ||
| 1 Year | -38.03% | ||
| 3 Years | -87.73% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -59.81 | |||
ROE last 12 Months | -36.52 | |||
ROA (5Y Avg) | -29.72 | |||
ROA last 12 Months | -35.37 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -36.52 | |||
Return on invested Capital Q | -9.65 | |||
Return on invested Capital Y | -40.49 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.90 | ||||
| 1.20 | ||||
| 144.92 | ||||
| - | ||||
| -5.90 | ||||
| -0.73 | ||||
| 1.20 | ||||
| 2.18 | ||||
| 32.49M | ||||
| Forward PE | -2.52 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 37.90 | ||||
| 39.30 | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 859.00 | ||||
| -2 817.50 | ||||
| -1 276.00 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.26M | ||||
| 0.02 | ||||
| -40.13 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | -0.21 | -0.22 | -4.76 |
| Q04 2020 | -0.24 | -0.20 | 16.67 |
| Q03 2020 | -0.30 | -0.24 | 20.00 |
| Q02 2020 | -0.29 | -0.27 | 6.90 |
| Q01 2020 | -0.33 | -0.34 | -3.03 |
| Q04 2019 | -0.59 | -0.41 | 30.51 |
| Q03 2019 | -0.46 | -0.44 | 4.35 |
| Q02 2019 | -0.52 | -0.36 | 30.77 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | -0.25 | 3.85 | Positive |
| 9/2021 QR | -0.28 | 3.45 | Positive |
| 12/2021 FY | -1.04 | -1.96 | Negative |
| 12/2022 FY | -1.04 | -11.83 | Negative |
| Next Report Date | 12th Aug 2021 |
| Estimated EPS Next Report | -0.25 |
| Estimates Count | 7 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 144.32K |
| Shares Outstanding | 68.17M |
| Trades Count | 759 |
| Dollar Volume | 1.74M |
| Avg. Volume | 820.77K |
| Avg. Weekly Volume | 210.58K |
| Avg. Monthly Volume | 645.99K |
| Avg. Quarterly Volume | 1.18M |
Aptinyx Inc. (NASDAQ: APTX) stock closed at 2.66 per share at the end of the most recent trading day (a -1.12% change compared to the prior day closing price) with a volume of 144.88K shares and market capitalization of 181.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Aptinyx Inc. CEO is Norbert G. Riedel.
The one-year performance of Aptinyx Inc. stock is -38.03%, while year-to-date (YTD) performance is -23.12%. APTX stock has a five-year performance of %. Its 52-week range is between 2.3 and 6.47, which gives APTX stock a 52-week price range ratio of 8.63%
Aptinyx Inc. currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 1.20, a price-to-sale (PS) ratio of 144.92, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -35.37%, a ROC of -36.52% and a ROE of -36.52%. The company’s profit margin is -%, its EBITDA margin is -2 817.50%, and its revenue ttm is $1.26 Million , which makes it $0.02 revenue per share.
Of the last four earnings reports from Aptinyx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Aptinyx Inc.’s next earnings report date is 12th Aug 2021.
The consensus rating of Wall Street analysts for Aptinyx Inc. is Strong Buy (1), with a target price of $9.71, which is +265.04% compared to the current price. The earnings rating for Aptinyx Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptinyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptinyx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.46, ATR14 : 0.17, CCI20 : -93.40, Chaikin Money Flow : -0.12, MACD : -0.06, Money Flow Index : 32.93, ROC : -2.21, RSI : 43.27, STOCH (14,3) : 31.58, STOCH RSI : 0.31, UO : 54.12, Williams %R : -68.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptinyx Inc. in the last 12-months were: Andrew Kidd (Option Excercise at a value of $0), Ashish Khanna (Option Excercise at a value of $0), Norbert G. Riedel (Option Excercise at a value of $0)
Aptinyx Inc.
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
CEO: Norbert G. Riedel
Telephone: +1 847 871-0377
Address: 909 Davis Street, Evanston 60201, IL, US
Number of employees: 43
